At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 7, 2026 at 16:01 ET
Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S. launch of AVLAYAH (tividenofusp alfa) for Hunter syndrome, the first medicine to cross the blood-brain barrier via transferrin receptor. The company also secured $200M in royalty financing and has a robust pipeline with key readouts expected by end of 2026.
- FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome on March 25, 2026
- First commercial patients dosed in April 2026; launch operational with payers engaged
- Received $200M gross proceeds from Royalty Pharma synthetic royalty funding agreement
- Cash, cash equivalents and marketable securities of $1.05B as of March 31, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access